PF-06936308

**PF-06936308**, also called **VBIR-2**, was a Pfizer-developed vaccine-based cancer immunotherapy regimen evaluated in a Phase 1 study for advanced non-small cell lung cancer and metastatic triple-negative breast cancer. The regimen used a chimpanzee adenovirus serotype 68 vector vaccine prime and a plasmid-DNA booster encoding undisclosed tumor-associated antigens, together with the checkpoint inhibitors tremelimumab and sasanlimab. The vaccine components were intended to induce tumor-antigen-specific T-cell responses, while tremelimumab and sasanlimab were intended to relieve CTLA-4- and PD-1-mediated immune checkpoint suppression, respectively. The study was stopped early because of a Pfizer development-strategy change. ([pfizer.com](https://www.pfizer.com/sites/default/files/plsr-studies/C3621001%20Plain%20Language%20Study%20Results%20Summary%20%28PLSRS%29%20Phase%201%20PK%20Primary%20Endpoint.pdf))

Other names

Vaccine-Based Immunotherapy Regimen-2VBIR-2VBIR2VBIR 2